NY-ZOOP
Led by a robust team of Web3 developers and former OnlyFans executives, Zoop is set to launch their digital collectable trading platform powered by Polygon , the decentralized Ethereum scaling ecosystem. Zoop’s platform allows users to buy, sell, collect and trade 3D digital playing cards of their favorite celebrities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220526005159/en/
On Zoop, fans can acquire officially licensed, limited edition digital cards, and are able to sell and trade them in a secondary market.
“Zoop is the trusted home for authentic celebrity card drops, enabling all fans, regardless of their technical expertise, to participate in the web3.0 space. We hold users' hands as they compete in acquiring digital collectables in the auction process, show off their holdings to friends and ‘collect-to-connect’ with their favorite celebrities of today and tomorrow. Zoop provides access to communities based on the cards users own, and rewards points to users for their interactions with each other and within these communities. We are excited to be launching Summer 2022,” says RJ Phillips, Founder and co-CEO of Zoop. “It’s a win for the celebrities, creates excitement for the fans and a new way for brands to connect with their customers,” he said.
Zoop is capitalizing on the booming blockchain gamification market, which grew to a $40 billion industry in 2021. And, by 2026, the industry is predicted to grow to $147 billion . By opening up the platform and combining it with today’s influencer-driven creator economy, Zoop’s app allows fans to collect 3D digital trading cards from their favorite influencers and celebrities, fostering a closer connection between fan and influencer. Fans can buy, sell, and trade cards, as well as compete in competitions and challenges to gain points, unlocking special rewards including access to like- minded communities. Zoop’s inclusive ecosystem is creating value for digital trading cards by enabling a fully transparent leaderboard.
The Zoop team will be led by co-CEOs Tim Stokely, tech Entrepreneur and founder of OnlyFans, and RJ Phillips. Tim, who will be joining the team in time for the launch this summer, brings extensive knowledge of the creator economy and a proven track record in building a true tech unicorn while RJ’s expertise in growth and scaling make for the perfect leadership team. Together, Tim and RJ plan to leverage their past career successes and knowledge of the creator economy to ultimately scale Zoop into a global digital trading card ecosystem that drives value for both creators and fans alike.
As a precursor to its initial launch, Zoop is offering a limited number of pre-launch Priority Passes (PP), which reward the earlier adopters with a host of perks, both in-app and real-life, in addition to exclusive airdrops only for PP holders. The first batch of these Priority Passes are available now at mint.zoopcards.com .
Zoop will be building its digital marketplace on the globally recognized Polygon blockchain network. Like Zoop, Polygon believes in Web3 for all, making them an ideal partner and blockchain of choice for the Zoop platform. Their low transaction costs and high security standard make card trading on Zoop safe and accessible for all. Additionally, Polygon’s sustainability commitment to make all their NFTs carbon-negative by the end of 2022 was another important factor for Zoop.
“We're delighted to be working with the Zoop team as they build out their platform on Polygon. Zoop aligns with our mission to bring Web3 technologies to a much broader demographic, and allowing fans to connect to their favorite celebrities via Polygon is another step towards this goal," said Michael Blank, COO of Polygon Studios, who has been providing Zoop with a suite of services such as technical support, Web3 game design and distribution, asset expansion and more.
Zoop's announcement comes just weeks after Instagram began minting their non-fungible tokens (NFTs) on Polygon's carbon-neutral network as well.
About Zoop
Zoop is building an entire ecosystem based on officially licensed celebrity digital trading cards. Fans are easily able to buy, sell, trade and collect the celebrities and influencers they idolize and admire through cutting edge blockchain technology. On Zoop, fans can build out their card collections and earn fan rewards with exclusive celebrity experiences whilst forging communities of like-minded collectors. Zoop cards garner authenticity through official partnerships with an unrivaled roster of celebrities and brands onboard. To learn more visit www.zoopcards.com .
Website | Twitter | Telegram | LinkedIn | Discord | Instagram | Facebook | Mint Page | Support Twitter | Medium | Tim’s Instagram | RJ’s Instagram
About Polygon
Polygon is the leading platform for Ethereum scaling and infrastructure development. Its growing suite of products offers developers easy access to all major scaling and infrastructure solutions: L2 solutions (ZK Rollups and Optimistic Rollups), sidechains, hybrid solutions, stand-alone and enterprise chains, data availability solutions, and more. Polygon’s scaling solutions have seen widespread adoption with 19,000+ applications hosted, 3.4B+ total transactions processed, ~135M+ unique user addresses, and $5B+ in assets secured.
If you're an Ethereum Developer, you're already a Polygon developer! Leverage Polygon’s fast and secure txns for your dApp, get started here .
Website | Twitter | Ecosystem Twitter | Developer Twitter | Studios Twitter | Telegram | LinkedIn | Reddit | Discord | Instagram | Facebook
About Polygon Studios
Polygon Studios aims to be the home of the most popular blockchain projects in the world. The Polygon Studios team is focused on supporting developers building decentralized apps on Polygon by providing Web2 and Web3 teams with a suite of services such as developer support, partnership, strategy, go-to-market, and technical integrations. Polygon Studios supports projects from OpenSea to Prada, from Adidas to Draft Kings and Decentral Games to Ubisoft.
Twitter | Facebook | Instagram | Telegram | Tiktok | LinkedIn
DISCLAIMER: Except where otherwise noted, the information contained in this release is as of May 26, 2022. We assume no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments. We cannot guarantee that any forward-looking statement will be realized. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Readers are cautioned not to put undue reliance on forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005159/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom